SYBX - Synlogic, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.44
-0.03 (-0.46%)
As of 3:12PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.47
Open6.43
Bid6.38 x 1100
Ask6.41 x 1000
Day's Range6.37 - 6.55
52 Week Range5.75 - 14.59
Volume129,771
Avg. Volume162,871
Market Cap204.337M
Beta (3Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)-2.00
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.22
Trade prices are not sourced from all markets
  • Business Wire8 days ago

    Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development

    Synlogic, Inc., (SYBX), a clinical stage company developing a novel class of Synthetic BioticTM therapeutics, today announced positive top-line clinical data from patient cohorts of a randomized, double-blind, placebo-controlled Phase 1/2a study of SYNB1618, which is being developed for the treatment of phenylketonuria (PKU). The study’s primary objectives were to evaluate safety and tolerability of an early liquid formulation. Exploratory outcomes were related to the assessment of the pharmacodynamic effects of SYNB1618, including measurement of previously identified biomarkers related to SYNB1618’s engineered ability to consume phenylalanine (Phe).

  • Zacks Small Cap Research22 days ago

    American Gene Technologies: The Software Revolution for the Next 100 Years

    By John Vandermosten, CFA American Gene Technologies (AGT) is a genetic medicines company developing a portfolio of therapies that employ the company’s proprietary lentiviral vector (LV) platform to focus ...

  • Business Wirelast month

    Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines

    Synlogic, Inc. (SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform.

  • Synlogic (SYBX) Enters Cancer Collaboration with Roche
    Zacks2 months ago

    Synlogic (SYBX) Enters Cancer Collaboration with Roche

    Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.

  • Business Wire2 months ago

    Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic™ medicine, SYNB1891, a dual innate immune activator engineered to express a STING agonist, in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq®) in patients with advanced solid tumors. Synlogic expects to file an Investigational New Drug (IND) application with the U.S. Federal Drug Administration (FDA) in the second half of 2019 for SYNB1891 to enable the company to begin an open-label Phase 1 clinical trial to evaluate the candidate as a monotherapy and a combination treatment with atezolizumab.

  • Synlogic, Inc. (SYBX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Synlogic, Inc. (SYBX) Q1 2019 Earnings Call Transcript

    SYBX earnings call for the period ending March 31, 2019.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SYBX earnings conference call or presentation 9-May-19 9:00pm GMT

    Q1 2019 Synlogic Inc Earnings Call

  • Business Wire2 months ago

    Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update

    – Company will host a conference call and webcast at 5:00 pm ET today –

  • Business Wire3 months ago

    Synlogic Announces First Quarter 2019 Conference Call and Webcast

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market closes on Thursday, May 9, 2019. The press release will be followed by a conference call at 5:00 pm ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

  • Business Wire3 months ago

    Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced that data demonstrating its development of a robust and reproducible process to generate a solid oral formulation of its Synthetic Biotic medicine, SYNB1618, are being presented today at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). Synlogic is developing SYNB1618 for the treatment of phenylketonuria (PKU).

  • Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer
    Investor's Business Daily3 months ago

    Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer

    Big Pharma is rapidly increasing its investments into biotech companies aiming to treat disease by targeting the microbiome. Some are also working on using bacterial strains as drugs.

  • Could Synlogic, Inc.'s (NASDAQ:SYBX) Investor Composition Influence The Stock Price?
    Simply Wall St.3 months ago

    Could Synlogic, Inc.'s (NASDAQ:SYBX) Investor Composition Influence The Stock Price?

    A look at the shareholders of Synlogic, Inc. (NASDAQ:SYBX) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders...

  • Business Wire3 months ago

    Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

    Synlogic, Inc., (SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of its Synthetic BioticTM medicines will be presented at the upcoming 22nd Annual Meeting of the American Society of Gene & Cell Therapy, which is being held from April 29 to May 2, 2019, in Washington, DC. The presentation will focus on preparation and characteristics of a solid oral preparation of SYNB1618, Synlogic’s synthetic biotic medicine for the treatment of phenylketonuria (PKU). Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer
    Business Wire3 months ago

    Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer

    Synlogic, Inc. (SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy, M.D., as Chief Scientific Officer. Dr. Plevy will have responsibility for Synlogic’s research organization and will report to Aoife Brennan, M.B., Ch.B., Synlogic’s president and chief executive officer.

  • Business Wire4 months ago

    Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of SYBX earnings conference call or presentation 12-Mar-19 12:00pm GMT

    Q4 2018 Synlogic Inc Earnings Call

  • Business Wire4 months ago

    Synlogic to Webcast Presentation at the Oppenheimer 29th Annual Healthcare Conference

    Synlogic (SYBX) announced today that Caroline Kurtz, Ph.D., Synlogic’s Head of Metabolism, will provide a corporate update at Oppenheimer’s 29th Annual Healthcare Conference at 3:20 pm ET on Wednesday, March 20, 2019, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease.

  • Business Wire4 months ago

    Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    – Ended 2018 with approximately $123 million in cash and investments, which provides runway through 2020 –

  • Business Wire5 months ago

    Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the advancement of Synthetic Biotic medicines to the lead optimization stage in its collaboration with AbbVie, a global biopharmaceutical company, to develop an oral treatment for inflammatory bowel disease (IBD). "Synlogic is a leader in the use of synthetic biology for the development of novel bacterial therapeutics," said, Lisa Olson Ph.D., Vice President, Immunology Research, AbbVie.

  • Business Wire5 months ago

    Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2018 financial results before the market opens on Tuesday, March 12, 2019. During the conference call, the Company will review its financial results and provide a corporate update. The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers.

  • Business Wire5 months ago

    Synlogic to Present at Investor Conferences in March

    Cowen and Company 39th Annual Health Care Conference at 11:20 am ET, on Monday, March 11, 2019, in Boston. Live webcasts of the presentations can be accessed under “Event Calendar” in the Investors & Media section of the Company’s website. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Business Wire5 months ago

    Synlogic to Webcast Presentation at the SVB Leerink 8th Annual Global Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the SVB Leerink 8th Annual Global Healthcare Conference at 1:30 pm ET on Thursday, February 28, 2019, in New York City. A live webcast of the presentation can be accessed under “Event Calendar” in the Investors & Media section of the Company’s website. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors
    Business Wire5 months ago

    Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Patricia N. Hurter, Ph.D., Senior Vice President of Pharmaceutical and Preclinical Sciences at Vertex Pharmaceuticals, Inc., to its board of directors. “I am delighted to welcome Trish to our Board,” said Aoife Brennan, M.B., Ch.B., Synlogic’s president and chief executive officer.

  • Business Wire6 months ago

    Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Science Translational Medicine of clinical data from its Phase 1 clinical study in healthy volunteers and supporting preclinical data from its investigational Synthetic Biotic candidate, SYNB1020. The data support the continued development of SYNB1020 which is currently being evaluated in a Phase 1b/2a clinical trial in patients with cirrhosis and elevated blood ammonia.

  • Business Wire7 months ago

    Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts

    Synlogic, Inc. (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today provided an overview of recent progress and outlined key objectives and anticipated milestones for 2019. “2018 was a significant year for Synlogic as we advanced our two lead clinical programs and platform. In addition, we broadened our pipeline with the addition of our first immuno-oncology development candidate, SYNB1891,” said Aoife Brennan, M.B. Ch.B., Synlogic’s president and chief executive officer.